Shilpa Medicare Management
Management criteria checks 4/4
Shilpa Medicare's CEO is Vishnukanth Bhutada, appointed in Aug 2022, has a tenure of 2.42 years. total yearly compensation is ₹35.00M, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 8.87% of the company’s shares, worth ₹6.17B. The average tenure of the management team and the board of directors is 2.7 years and 3.3 years respectively.
Key information
Vishnukanth Bhutada
Chief executive officer
₹35.0m
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 2.4yrs |
| CEO ownership | 8.9% |
| Management average tenure | 2.7yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
These 4 Measures Indicate That Shilpa Medicare (NSE:SHILPAMED) Is Using Debt Reasonably Well
Jan 02
What Shilpa Medicare Limited's (NSE:SHILPAMED) 28% Share Price Gain Is Not Telling You
Sep 12Shilpa Medicare Limited's (NSE:SHILPAMED) 29% Price Boost Is Out Of Tune With Revenues
Jul 05What Shilpa Medicare Limited's (NSE:SHILPAMED) 27% Share Price Gain Is Not Telling You
Apr 12Shilpa Medicare Limited's (NSE:SHILPAMED) Shares Climb 28% But Its Business Is Yet to Catch Up
Feb 21Shilpa Medicare (NSE:SHILPAMED) Takes On Some Risk With Its Use Of Debt
Jan 02These 4 Measures Indicate That Shilpa Medicare (NSE:SHILPAMED) Is Using Debt Extensively
Jul 17Shilpa Medicare (NSE:SHILPAMED) Seems To Be Using A Lot Of Debt
Mar 17Increases to CEO Compensation Might Be Put On Hold For Now at Shilpa Medicare Limited (NSE:SHILPAMED)
Sep 22Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10
Sep 07Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10
Aug 14Here's Why Shilpa Medicare (NSE:SHILPAMED) Is Weighed Down By Its Debt Load
Jan 27Shareholders May Not Be So Generous With Shilpa Medicare Limited's (NSE:SHILPAMED) CEO Compensation And Here's Why
Sep 21Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?
Jun 17If You Like EPS Growth Then Check Out Shilpa Medicare (NSE:SHILPAMED) Before It's Too Late
May 31Shilpa Medicare Limited's (NSE:SHILPAMED) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Mar 07Shilpa Medicare Limited (NSE:SHILPAMED) Analysts Are Reducing Their Forecasts For Next Year
Feb 20CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹611m |
| Jun 30 2024 | n/a | n/a | ₹448m |
| Mar 31 2024 | ₹35m | ₹35m | ₹319m |
| Dec 31 2023 | n/a | n/a | -₹7m |
| Sep 30 2023 | n/a | n/a | -₹119m |
| Jun 30 2023 | n/a | n/a | -₹321m |
| Mar 31 2023 | ₹35m | ₹35m | -₹325m |
| Dec 31 2022 | n/a | n/a | ₹51m |
| Sep 30 2022 | n/a | n/a | ₹213m |
| Jun 30 2022 | n/a | n/a | ₹599m |
| Mar 31 2022 | ₹97m | ₹16m | ₹607m |
| Dec 31 2021 | n/a | n/a | ₹395m |
| Sep 30 2021 | n/a | n/a | ₹376m |
| Jun 30 2021 | n/a | n/a | ₹631m |
| Mar 31 2021 | ₹97m | ₹16m | ₹1b |
| Dec 31 2020 | n/a | n/a | ₹2b |
| Sep 30 2020 | n/a | n/a | ₹2b |
| Jun 30 2020 | n/a | n/a | ₹2b |
| Mar 31 2020 | ₹99m | ₹10m | ₹2b |
| Dec 31 2019 | n/a | n/a | ₹1b |
| Sep 30 2019 | n/a | n/a | ₹1b |
| Jun 30 2019 | n/a | n/a | ₹944m |
| Mar 31 2019 | ₹75m | ₹10m | ₹1b |
| Dec 31 2018 | n/a | n/a | ₹1b |
| Sep 30 2018 | n/a | n/a | ₹1b |
| Jun 30 2018 | n/a | n/a | ₹1b |
| Mar 31 2018 | ₹81m | ₹16m | ₹1b |
Compensation vs Market: Vishnukanth's total compensation ($USD405.06K) is about average for companies of similar size in the Indian market ($USD351.05K).
Compensation vs Earnings: Vishnukanth's compensation has been consistent with company performance over the past year.
CEO
Vishnukanth Bhutada (62 yo)
2.4yrs
Tenure
₹35,000,000
Compensation
Mr. Vishnukanth Chaturbhuj Bhutada, B. Pharm. serves as the Managing Director of Shilpa Medicare Limited since August 11, 2022 . Mr. Bhutada joined Shilpa Medicare Limited in November 1987.He serves as th...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Director | 2.4yrs | ₹35.00m | 8.87% ₹ 6.2b | |
| Chief Financial Officer | 3.7yrs | ₹14.73m | 0.0023% ₹ 1.6m | |
| VP of Projects & Operations and Whole-Time Director | no data | ₹16.26m | 0.032% ₹ 22.5m | |
| Company Secretary & Compliance Officer | 2.7yrs | ₹4.51m | no data | |
| Chief Operating Officer of Formulations | no data | ₹26.95m | no data | |
| President of Global R&D | no data | ₹11.50m | no data | |
| Senior Vice President – Domestic Formulations and Biologics | no data | ₹3.90m | no data | |
| Senior Vice President of Formulation | no data | ₹12.50m | no data | |
| Executive Vice President – Formulations for Small Molecules | no data | ₹2.50m | no data | |
| Vice President | no data | ₹12.77m | no data | |
| Senior Vice President of Technical | no data | ₹6.06m | no data | |
| Chief Human Resource Officer | no data | no data | no data |
2.7yrs
Average Tenure
53.5yo
Average Age
Experienced Management: SHILPAMED's management team is considered experienced (2.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Director | 37.2yrs | ₹35.00m | 8.87% ₹ 6.2b | |
| VP of Projects & Operations and Whole-Time Director | 5.3yrs | ₹16.26m | 0.032% ₹ 22.5m | |
| Non-Executive Independent Director | 3.3yrs | ₹3.00m | no data | |
| Non-Executive Independent Director | 2.5yrs | ₹3.00m | no data | |
| Non-Executive Independent Director | 3.3yrs | ₹4.00m | 0.0092% ₹ 6.4m | |
| Non-Executive Chairman | 36.8yrs | ₹350.00k | 3.3% ₹ 2.3b | |
| Independent Women Director | 2.4yrs | ₹1.80m | no data |
3.3yrs
Average Tenure
62yo
Average Age
Experienced Board: SHILPAMED's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/22 22:21 |
| End of Day Share Price | 2025/01/22 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shilpa Medicare Limited is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Antique Stockbroking Ltd. |
| Harith Ahamed | Avendus Spark |
| Prathamesh Masdekar | BP Wealth Management Private Limited |